REGENXBIO Inc.

Stage 4 · Declining · week 5

As of Oct 22, 2026, REGENXBIO is in Stage 4, the downtrend phase, now in week 5 (since Sep 18, 2026). It closed at $7.17, 55.1% below its 52-week high and below its 200-day average, which is falling.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. More about the company

$7.17

+0.00% today

$473M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is RGNX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 15w

S4 16w

S4 31w

S2 22w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 15w → S1 8w → S4 6w → S1 2w → S2 6w → S3 3w → S4 16w → S1 1w → S4 31w → S1 7w → S2 5w → S3 6w → S2 22w → S3 5w → S4 7w → S1 1w → S4 6w → S1 6w → S2 4w → S3 1w → S4 5w current

Total tracked: 165 weeks across 21 stage runs.

RGNX among Biotechnology333rd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…333	RGNXREGENXBIO Inc.	Stage 4 · wk 5	26	−4.4%

vs 52W High

-55.1%

$5.65 lo$15.98 hi

55.1% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 5

1w13w26w

Week 5, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-23.8%

200 DMA: $9.41 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.82x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-4.4%

-26.3%

-20.2%

YTD

-47.2%

-45.2%

Scan Membership

Breakout Watch

Latest: 2025-06-25

6 appearances in last 60 days. First seen: 2020-01-31.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 5 · Vol 0.82x

2026-10-21S4

Wk 5 · Vol 0.56x

2026-10-20S4

Wk 5 · Vol 0.95x

2026-10-19S4

Wk 5 · Vol 0.94x

2026-10-16S4

Wk 5 · Vol 0.87x

2026-10-15S4

Wk 4 · Vol 0.88x

2026-10-14S4

Wk 4 · Vol 1.13x

2026-10-13S4

Wk 4 · Vol 1.00x

2026-10-12S4

Wk 4 · Vol 1.49x

2026-10-09S4

Wk 4 · Vol 0.63x

2026-10-08S4

Wk 3 · Vol 1.68x

2026-10-07S4

Wk 3 · Vol 0.74x

Moving averages & range

50 DMA

$8.49

200 DMA

$9.41

52W High

$15.98

52W Low

$5.65

5D Low

$6.93

Resistance levels (recent highs)

20d High

$8.09

60d High

$12.02

120d High

$15.65

250d High

$15.98

Next resistance

+12.8%

to 20d High

ROE

-137.6%

Profit margin -112.6%

Dividend Yield

0.00%

P/B 5.4

REGENXBIO: quick answers

What stage is REGENXBIO in?

As of Oct 22, 2026, REGENXBIO (RGNX) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 18, 2026 and is in week 5. What the four stages mean

Is REGENXBIO in an uptrend?

No. REGENXBIO is in a Stage 4 downtrend. It trades 23.8% below its 200-day average, which is falling.

How far is REGENXBIO from its 52-week high?

REGENXBIO closed at $7.17 on Oct 22, 2026, 55.1% below its 52-week high of $15.98. Its 52-week low is $5.65.

How has REGENXBIO performed over the past year?

As of Oct 22, 2026, REGENXBIO is down 45.2% over the past year and down 47.2% so far in 2026.

Which sector and industry is REGENXBIO in?

REGENXBIO is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.